Holen Sie sich die Stockscreener-App
4.04
1.49%
-0.08
Schlusskurs vom Vortag:
$4.12
Offen:
$4.13
24-Stunden-Volumen:
152.52K
Relative Volume:
0.69
Marktkapitalisierung:
$211.88M
Einnahmen:
$21.05M
Nettoeinkommen (Verlust:
$-89.22M
KGV:
-1.3979
EPS:
-2.89
Netto-Cashflow:
$-64.50M
1W Leistung:
-15.79%
1M Leistung:
-22.98%
6M Leistung:
-56.26%
1J Leistung:
-2.90%
1-Tages-Spanne:
$3.93
$4.1679
1-Wochen-Bereich:
$3.93
$4.85
52-Wochen-Spanne:
$3.73
$9.69
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
880 WINTER STREET, WALTHAM
Vergleichen Sie TCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TCRX | 4.03 | 211.88M | 21.05M | -89.22M | -64.50M | -2.89 |
| VRTX | 449.80 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.38 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.15 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.49 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
LMR Partners LLP Trims Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Tscan therapeutics sees $4,113 stock purchase by Lynx1 capital - Investing.com India
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? - MSN
Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Wedbush Research Analysts Boost Earnings Estimates for TCRX - MarketBeat
TScan Therapeutics Inc (TCRX) Quarterly 10-Q Report - Quartzy
Wedbush Has Positive Forecast for TCRX FY2028 Earnings - MarketBeat
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts By Investing.com - Investing.com Nigeria
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts - Investing.com India
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Needham & Company LLC Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World
TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks
Tscan Therapeutics earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
New Blood Cancer Treatment Shows Continued Response - Streetwise Reports
Tscan Therapeutics Inc’s (TCRX) 7.56% Increase Justifies A Second Look - Stocks Register
TScan Therapeutics' (TCRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet? - Simply Wall St
TScan Therapeutics' SWOT analysis: innovative therapy stock faces pivotal year - Investing.com Australia
TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire
TScan's Blood Cancer Trial Shows Zero Relapses: Breakthrough Phase 1 Results | TCRX Stock News - StockTitan
Waltham cancer biotech adds to real estate footprint - The Business Journals
TScan Therapeutics (NASDAQ:TCRX) Enters Second Amendment for Lease Agreement to Expand Operations at Winter Street FacilityOn October 28, 2024, TScan Therapeutics, Inc. finalized a second amendment to its lease agreement with PPF OFF 828-83 - Defense World
TScan expands Waltham facility with additional lease - Investing.com India
TScan expands Waltham facility with additional lease By Investing.com - Investing.com UK
Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
The Manufacturers Life Insurance Company Invests $90,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Where are the Opportunities in (TCRX) - Stock Traders Daily
BTIG Initiates Coverage of TScan Therapeutics (TCRX) with Buy Recommendation - MSN
Bank of Montreal Can Acquires Shares of 120,454 TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Bank of Montreal Can Invests $749,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
(TCRX) On The My Stocks Page - Stock Traders Daily
TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Lifted by Marshall Wace LLP - MarketBeat
American Century Companies Inc. Increases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TCRXTScan Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
TScan Therapeutics Announces Upcoming Presentations at the - GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - StockTitan
Reviewing TScan Therapeutics (NASDAQ:TCRX) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Tscan Therapeutics Inc [TCRX] Stock bought by Insider Klencke Barbara for $26450.0 - Knox Daily
Was there any good news for Tscan Therapeutics Inc (TCRX) stock in the last session? - US Post News
Market Momentum Report: Tscan Therapeutics Inc (TCRX)’s Negative Close at 4.98 - The Dwinnex
TScan Therapeutics's SWOT analysis: biotech stock faces pivotal year - Investing.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Significant Growth in Short Interest - MarketBeat
92,832 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Bought by Troluce Capital Advisors LLC - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Barbara Klencke Acquires 5,000 Shares - Defense World
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com South Africa
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):